公開研究報告

JPMorgan Chase & Co.

JPMNYSE

增持

Gradually increase long exposure to JPM with disciplined entry and dynamic risk controls.

Eli Lilly and Company

LLYNYSE

增持

Overweight LLY with disciplined, phased accumulation: initiate 25% at $1,280, add 25% at $1,300, and 25% at $1,350 — stop-loss at $1,150.

Berkshire Hathaway Inc. Class A

BRK.ANYSE

持有

Hold current position in BRK.A, using $745,000 and $795,000 as key price-based review triggers.

SELLAS Life Sciences Group, Inc.

SLSNASDAQ

持有

Hold current position in SLS; await definitive GPS Phase 3 readout or technical breakout/breakdown for adjustment.

Climb Bio, Inc.

CLYMNASDAQ

持有

Hold current position with disciplined price-based contingencies and catalyst-driven reassessment.

New Era Energy & Digital, Inc.

NUAINASDAQ

持有

Hold current position; add only upon verified PPA or construction commencement with milestones.

Mega Fortune Company Limited

MGRTNASDAQ

賣出

Exit all existing MGRT positions immediately; do not initiate new long exposure under any circumstance.

AXT, Inc.

AXTINASDAQ

持有

Hold current position with strict $85.00 stop-loss and await October 29 earnings for definitive thesis confirmation.

BUUU Group Limited Class A

BUUUNASDAQ

賣出

Sell all BUUU exposure immediately; do not initiate new long positions.

Shattuck Labs, Inc.

STTKNASDAQ

持有

Hold current exposure to STTK, awaiting Q3 2026 Phase 2b trial initiation as the decisive inflection point.

Relmada Therapeutics Inc

RLMDNASDAQ

持有

Hold existing RLMD position; await confirmed breakout above $5.09 or new insider purchases above $4.50 before adjusting exposure.

Q32 Bio Inc

QTTBNASDAQ

持有

Portfolio Manager’s Final Trading Decision

Erasca, Inc.

ERASNASDAQ

持有

Hold current position with partial profit-taking near $19.56 and a dynamic trailing stop starting at $17.49.

D

Damora Therapeutics, Inc.

DMRANASDAQ

持有

Hold current position; await Phase 1/2 data readouts in late 2026–early 2027 before reassessing.

XMAX, Inc.

XMAXNASDAQ

持有

Hold current position; await Q3 earnings or Aerora integration update before adjusting exposure.

Wolfspeed Inc

WOLFNYSE

買入

Buy WOLF on phased entry ahead of Q4 2026 earnings, targeting $50+ on revenue beat and short squeeze.

Relay Therapeutics, Inc.

RLAYNASDAQ

持有

Hold current position pending resolution of Zovega Phase 3 data, NCCN inclusion, or ReDiscover-2 updates.

Seagate Technology Holdings PLC

STXNASDAQ

持有

Hold current position; await Q1 2027 earnings for resolution of symmetric bull/bear evidence.